SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism
- 6 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 64 (3), 630-640
- https://doi.org/10.1007/s00125-020-05346-7
Abstract
Aims/hypothesis Congenital hyperinsulinism caused by mutations in the KATP-channel-encoding genes (KATPHI) is a potentially life-threatening disorder of the pancreatic beta cells. No optimal medical treatment is available for patients with diazoxide-unresponsive diffuse KATPHI. Therefore, we aimed to create a model of KATPHI using patient induced pluripotent stem cell (iPSC)-derived islets. Methods We derived iPSCs from a patient carrying a homozygous ABCC8V187D mutation, which inactivates the sulfonylurea receptor 1 (SUR1) subunit of the KATP-channel. CRISPR-Cas9 mutation-corrected iPSCs were used as controls. Both were differentiated to stem cell-derived islet-like clusters (SC-islets) and implanted into NOD-SCID gamma mice. Results SUR1-mutant and -corrected iPSC lines both differentiated towards the endocrine lineage, but SUR1-mutant stem cells generated 32% more beta-like cells (SC-beta cells) (64.6% vs 49.0%, p = 0.02) and 26% fewer alpha-like cells (16.1% vs 21.8% p = 0.01). SUR1-mutant SC-beta cells were 61% more proliferative (1.23% vs 0.76%, p = 0.006), and this phenotype could be induced in SUR1-corrected cells with pharmacological KATP-channel inactivation. The SUR1-mutant SC-islets secreted 3.2-fold more insulin in low glucose conditions (0.0174% vs 0.0054%/min, p = 0.0021) and did not respond to KATP-channel-acting drugs in vitro. Mice carrying grafts of SUR1-mutant SC-islets presented with 38% lower fasting blood glucose (4.8 vs 7.7 mmol/l, p = 0.009) and their grafts failed to efficiently shut down insulin secretion during induced hypoglycaemia. Explanted SUR1-mutant grafts displayed an increase in SC-beta cell proportion and SC-beta cell nucleomegaly, which was independent of proliferation. Conclusions/interpretation We have created a model recapitulating the known pathophysiology of KATPHI both in vitro and in vivo. We have also identified a novel role for KATP-channel activity during human islet development. This model will enable further studies for the improved understanding and clinical management of KATPHI without the need for primary patient tissue. Graphical abstractFunding Information
- Sigrid Juséliuksen Säätiö
- Academy of Finland (312437)
- Novo Nordisk Fonden (0057286)
- Diabetestutkimussäätiö
This publication has 51 references indexed in Scilit:
- Clinical and molecular characterisation of 300 patients with congenital hyperinsulinismActa Endocrinologica, 2013
- Glucose Metabolism in 105 Children and Adolescents After Pancreatectomy for Congenital HyperinsulinismDiabetes Care, 2012
- In vitro insulin secretion by pancreatic tissue from infants with diazoxide-resistant congenital hyperinsulinism deviates from model predictionsJCI Insight, 2011
- Congenital Hyperinsulinism in Brazilian Neonates: A Study of Histology, KATP Channel Genes, and Proliferation of β CellsPediatric and Developmental Pathology, 2010
- The Barrier of Hypoglycemia in DiabetesDiabetes, 2008
- Disease-Specific Induced Pluripotent Stem CellsCell, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Insulin receptors in β-cells are critical for islet compensatory growth response to insulin resistanceProceedings of the National Academy of Sciences of the United States of America, 2007
- Early positive exercise test and extensive coronary disease: Effect of antianginal therapyThe American Journal of Cardiology, 1985
- Glucose induces closure of single potassium channels in isolated rat pancreatic β-cellsNature, 1984